سعر ابيفيمي 400مجم/16مل فيال للحقن 2026

Bevacizumab biosimilar (reference product Avastin) supplied as a single-use 16 ml vial containing 400 mg bevacizumab (25 mg/ml) concentrate for dilution and intravenous infusion.

• Metastatic carcinoma of the colon or rectum (first line, with fluoropyrimidine-based chemotherapy)Population: AdultsEgyptian Drug Authority, European Medicines Agency (EMA)
• Metastatic breast cancer (first line, with paclitaxel or capecitabine in defined patients)Population: AdultsEgyptian Drug Authority, European Medicines Agency (EMA)
• Unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (with platinum-based chemotherapy, or with erlotinib if EGFR-activating mutations)Population: AdultsEgyptian Drug Authority, European Medicines Agency (EMA)
• Advanced and/or metastatic renal cell cancer (first line, with interferon alfa-2a)Population: AdultsEgyptian Drug Authority, European Medicines Agency (EMA)
• Epithelial ovarian, fallopian tube or primary peritoneal cancer (front-line and recurrent settings, in defined combinations)Population: AdultsEgyptian Drug Authority, European Medicines Agency (EMA)
• Persistent, recurrent or metastatic carcinoma of the cervix (with paclitaxel and cisplatin, or paclitaxel and topotecan)Population: AdultsEgyptian Drug Authority, European Medicines Agency (EMA)

• Bevacizumab: Binds vascular endothelial growth factor (VEGF) and prevents its interaction with VEGFR-1 and VEGFR-2 on endothelial cells, inhibiting endothelial proliferation, angiogenesis and VEGF-induced vascular permeability (EDA assessment report; US label).